- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02531269
Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period
Using European data from patients included in the Named Patient Program (NPP) and from the early post-marketing authorization period, the present study aims to describe patient characteristics and to describe the effectiveness of Daclatasvir (DCV)-based regimens in Europe. This will be a retrospective cohort study of patients who received treatment with a DCV-based regimen in the following context:
- Patients enrolled within the European NPP in one of the following countries Austria, Denmark, Italy, Sweden, Spain, Switzerland, United Kingdom; or
- In those countries where DCV is commercially available (ie, Sweden, Germany, United Kingdom), patients who received DCV during the early post-marketing authorization period
The results of this study will contribute to a better understanding of effectiveness of DCV-based regimens in a population that differs from population in the clinical trials, and therefore will provide additional valuable information to inform clinical practice.
This study intends to estimate primarily the effectiveness of DCV-based regimens as measured by the sustained virologic response at post treatment follow-up visit week 12 (SVR12). As well as estimate the effectiveness of DCV-based regimens as measured by SVR12 after the end of Hepatitis C virus (HCV).
This study intends also to describe as secondary objectives the characteristics (ie, demographic and clinical characteristics and treatment patterns of patients starting a new DCV-based regimens) of patients receiving DCV as well as the effectiveness of DCV-based regimens as measured by:
- On-treatment virological response at post treatment follow-up visit Week 4; and
- Virological response at the end of treatment (EOT); and
- The sustained viral response at post treatment follow-up visit Week 4 (SVR4) and post treatment follow-up visit Week 24 (SVR24); and
- The occurrence of virological failure (on-treatment and relapse).
An exploratory objective will be to assess the concordance between SVR4 and SVR12 among the overall population treated with DCV.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
-
Basel, Suíça
- Local Institution
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
Patients participating in the DCV NPP from 7 European countries (Austria, Denmark, Italy, Sweden, Spain, Switzerland, and UK). The following patients were eligible to participate in the NPP
- The patient have a serious or life-threatening condition that is impacting life expectancy within 12 months.
- There are no comparable or satisfactory alternative treatments options exist for the patient, and/or currently available treatment options have been exhausted.
- The patient was ineligible to participate in a clinical trial, or there was no ongoing clinical trial in the patient´s country of residence to treat his/her HCV-infection.
- In countries where DCV is commercially available at time of study initiation(Sweden, UK, and Germany), patients treated with DCV during the early post-marketing authorization period.
- Patients initiating any DCV-based regimen during the inclusion periods.
- Recorded in one of the HCV data sources used for the study.
Exclusion Criteria:
- Patients included in the DCV Compassionate use program (CUP) (AI444-237 Protocol) open in 6 European countries (Germany, Austria, Sweden, Netherlands, Norway and UK) after Committee for Medicinal Products for Human Use (CHMP) opinion for the DCV CUP in Europe will be excluded since these patients will be analyzed as part of separate datasets.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
---|
Patients treated with DCV (NPP)+Sofosbuvir +/- Ribavirin (RBV)
|
Patients treated with DCV (NPP) + Simeprevir +/- RBV
|
Patients treated with DCV(post-marketing) + Sofosbuvir +/- RBV
|
Patients treated with DCV(post-marketing) + Simeprevir +/- RBV
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
SVR12
Prazo: Up to 36 months
|
Effectiveness of DCV-based regimens as measured by the SVR12, overall and in specific patient sub-populations
|
Up to 36 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
SVR4
Prazo: Up to 36 months
|
Effectiveness of DCV-based regimens as measured by SVR4
|
Up to 36 months
|
SVR24
Prazo: Up to 36 months
|
Effectiveness of DCV-based regimens as measured by SVR24
|
Up to 36 months
|
On-treatment Virological response at week 4 assessed by measuring viral load
Prazo: Up to 36 months
|
Up to 36 months
|
|
Virological response at the end of treatment (EOT) assessed by measuring viral load
Prazo: Up to 36 months
|
Up to 36 months
|
|
The occurrence of virological failure (on-treatment and relapse) assessed by measuring viral load
Prazo: Up to 36 months
|
Virological failure is defined as virologic breakthrough, other on-treatment failure or relapse, where:
|
Up to 36 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças do aparelho digestivo
- Infecções por vírus de RNA
- Doenças Virais
- Infecções
- Infecções transmitidas pelo sangue
- Doenças Transmissíveis
- Doenças do Fígado
- Infecções por Flaviviridae
- Hepatite, Viral, Humana
- Infecções por Enterovírus
- Infecções por Picornaviridae
- Hepatite Crônica
- Hepatite
- Hepatite A
- Hepatite C
- Hepatite C Crônica
Outros números de identificação do estudo
- AI444-319
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Hepatite C
-
Dokuz Eylul UniversityEge UniversityConcluídoMMP9 | TIMP1 | MMP9 -1562 C/T | TIMP1 372 T/CPeru
-
University College CorkDupont Applied BiosciencesRecrutamento
-
Trek Therapeutics, PBCConcluídoHepatite C crônica | Hepatite C Genótipo 1 | Hepatite C (VHC) | Infecção viral da hepatite CEstados Unidos, Nova Zelândia
-
Trek Therapeutics, PBCConcluídoHepatite C crônica | Hepatite C (VHC) | Hepatite C Genótipo 4 | Infecção viral da hepatite CEstados Unidos
-
Humanity and Health Research CentreBeijing 302 HospitalConcluídoInfecção Crônica por Hepatite CChina
-
University Hospital, GrenobleClinical Investigation Centre for Innovative Technology NetworkConcluídoC. Procedimento CirúrgicoFrança
-
Tripep ABInovio PharmaceuticalsDesconhecidoInfecção Crônica pelo Vírus da Hepatite CSuécia
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsRetiradoInfecção Crônica pelo Vírus da Hepatite CIsrael
-
Hadassah Medical OrganizationDesconhecidoInfecção Crônica pelo Vírus da Hepatite CIsrael